Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Summary
Bill A01937 aims to amend the public health law in New York by establishing requirements for practitioners before they issue prescriptions for schedule II opioids. Specifically, it mandates that practitioners consult with patients about the quantity of the opioid prescribed, inform them of the risks associated with opiate addiction, and document the rationale for the prescription in the patient's medical record. This legislation is designed to enhance patient awareness and promote safer prescribing practices in response to the opioid crisis.
Impact
If enacted, this bill would introduce new obligations for healthcare providers in New York regarding the prescription of schedule II opioids. It would require practitioners to engage in meaningful discussions with patients about their prescriptions, potentially leading to a decrease in opioid misuse and addiction. The documentation requirement may also improve accountability and tracking of opioid prescriptions within the healthcare system.
Sentiment
The sentiment surrounding Bill A01937 appears to be generally supportive, as it addresses a critical public health issue related to opioid addiction. Stakeholders, including healthcare professionals and patient advocacy groups, have expressed the need for increased patient education and responsible prescribing practices. However, there may be concerns regarding the additional administrative burden placed on practitioners.
Contention
Notable points of contention may arise from practitioners who feel that the added requirements could complicate the prescribing process and increase their workload. Some may argue that the bill could lead to delays in patient care or that it may not effectively address the underlying issues of opioid addiction. Additionally, there may be differing opinions on the adequacy of existing guidelines for opioid prescriptions versus the need for this legislation.
Same As
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Relates to patient counseling before issuing a prescription for a schedule II opioid; requires practitioners to consult with the patient regarding the quantity of the opioid and the patient's option to fill the prescription in a lesser quantity, and to inform the patient of the risks associated with opiate addiction and document the reason for the prescription.
Requires practitioners to provide counselling to patients about the potential addictive properties of opioids prior to prescribing such medications; requires pharmacists to provide counselling to patients about the potential addictive properties of opioids at the time a prescription for opioids is filled.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.